Vanguard Group Inc. Has $13.25 Billion Holdings in Stryker Corporation $SYK

Vanguard Group Inc. grew its holdings in Stryker Corporation (NYSE:SYK) by 1.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 33,500,571 shares of the medical technology company’s stock after purchasing an additional 440,607 shares during the period. Vanguard Group Inc. owned about 8.76% of Stryker worth $13,253,831,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after buying an additional 1,021,496 shares during the period. Geode Capital Management LLC increased its stake in shares of Stryker by 1.1% during the 2nd quarter. Geode Capital Management LLC now owns 7,393,611 shares of the medical technology company’s stock worth $2,910,445,000 after purchasing an additional 79,654 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after purchasing an additional 261,058 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of Stryker by 4.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after purchasing an additional 83,954 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in Stryker by 1.5% in the first quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock worth $750,223,000 after purchasing an additional 30,329 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on SYK. Truist Financial boosted their price target on Stryker from $392.00 to $400.00 and gave the stock a “hold” rating in a research report on Friday. Sanford C. Bernstein restated an “outperform” rating on shares of Stryker in a report on Monday, November 3rd. Wells Fargo & Company increased their price target on Stryker from $452.00 to $456.00 and gave the company an “overweight” rating in a report on Friday. Needham & Company LLC restated a “buy” rating and issued a $448.00 price objective on shares of Stryker in a research note on Friday. Finally, BTIG Research reiterated a “buy” rating and issued a $410.00 target price on shares of Stryker in a research note on Friday. Thirteen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $434.37.

Stryker Price Performance

NYSE:SYK opened at $359.45 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.78 and a quick ratio of 1.06. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19. The company has a fifty day moving average price of $371.28 and a 200 day moving average price of $381.16. The stock has a market cap of $137.46 billion, a P/E ratio of 47.61, a PEG ratio of 2.66 and a beta of 0.94.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Thursday, October 30th. The medical technology company reported $3.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.13 by $0.06. The company had revenue of $6.06 billion for the quarter, compared to the consensus estimate of $6.04 billion. Stryker had a net margin of 12.25% and a return on equity of 23.94%. The business’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.87 EPS. Stryker has set its FY 2025 guidance at 13.500-13.600 EPS. Analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current year.

Insider Activity at Stryker

In other news, CAO William E. Berry, Jr. sold 1,953 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $365.49, for a total transaction of $713,801.97. Following the sale, the chief accounting officer directly owned 2,833 shares in the company, valued at approximately $1,035,433.17. The trade was a 40.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 276,173 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $353.28, for a total value of $97,566,397.44. Following the completion of the transaction, the director owned 2,702,108 shares of the company’s stock, valued at $954,600,714.24. The trade was a 9.27% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 522,453 shares of company stock worth $185,516,867 over the last three months. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.